Dissertation > Excellent graduate degree dissertation topics show

DNA Prime/Protein Boost of Japanse Edcephalitis Virus NS1 Protein to Improve Immune Response in Mice

Author: WuPeng
Tutor: ChenZuoYan
School: Nanjing Agricultural College
Course: Preventive Veterinary Medicine
Keywords: Japanese encephalitis virus (JEV) nonstructural proteins 1 DNA vaccine subunit vaccine prime-boost immune
CLC: R392
Type: Master's thesis
Year: 2009
Downloads: 14
Quote: 0
Read: Download Dissertation


Japanese encephalitis virus (JEV) is a member of the Flavivirus genus of the Flaviviridae family. Japanese encephalitis virus is widely distributed in the south and southeast regions of Asia, including China, India, Japan, et al. It is a mosquito-borne flavivirus responsible for acute encephalitis in humans, with fatality rates ranging from 20% to as high as 50%. Most of the survivors display persistent neurological or psychological sequelae. Therefore, mass vaccination of swine can prevent disease in swine and help to prevent JE epidemics in humans. Thus there is an urgent need to develop more effective JE vaccines and to alter the strategies against this viral disease. In recent years, many studies have demonstrated the efficacy of genetically engineered vaccine for JEV. Vaccination has played an important role in the protection of mammal against virus infections. DNA priming/protein boosting is a vaccine strategy that use plasmid DNA encoding virus protein for the first immunization, then boost with protein-based vaccine as an augmentation. According to strategy of DNA priming/protein boosting, immunogenic efficacy for NS1 protein of Japanese Encephalitis Virus vaccine are tested. The study was unfolded through the following aspects.1. A synthetic NS1 gene of the Japanese encephalitis virus (JEV) was cloned into eukaryotic expression vector pcDNA3.0, named pcDNA-NS1. BHK-21 cells were then transfected with this recombinant plasmid. Recombinant protein was showed to transcript and express effectively by indirect immunofluorescence. Collect the cell supernatant after 48h transfection for Western blot, it showed the protein can interact with JEV positive anit-serum, proved its biological activity and antigenicity in vitro.2. NS1 gene was amplified and conjuncted to the expression vector pET-28a(+), named as pET-rNS1. Then the plasmid was transformed into host bacterium BL21 (DE3).After IPTG 4h later, cells were suspended in PBS. Cells were treated with ultrasonic, and then centrifuged with 10000rpm for 20min. Both the supernatant and pellet was analyzed by electrophoresis. It showed that the protein was existed in form of inclusion body. The inclusion body was dissolved with 8M urea and purified with His·Bind affinity chromatography according to the instruction manual. We got the 41kD recombinant protein. Western blot showed the specific anti-JEV activity.3. New strategy of immunity was used to investigate the immunogenic efficiency of the pcDNA-NS1 and pET-rNS1, mice (4-week-old, female) were randomly divided into five groups with eight of them each group. Mice were inoculated intramuscularly pcDNA-NS1(Ⅱ) at a dose of 50μg; Mice in group(Ⅰ)were injected with purified rNS1 at a dose of 200 pmol, Mice in group(Ⅲ) were injected with pcDNA-NS1+rNS1; The blank eukaryotic expression plasmid pcDNA3.0 and inactivated vaccine were used as controls. JEV specific neutralizing antibody titer was evaluated with virus neutralization test assay, furthermore, the production of JEV specific IFN-γand IL-4 in splenocytes was detected with commercial ELISA Kit. Data showed that the new vaccine strategy can induce humoral and cellular immune responses. The rank for neutralizing antibodies titers is the attenuated vaccine, pcDNA-NS1+rNS1, rNS1, pcDNA-NS1, and pcDNA3.0 from high to low. The production of gamma interferon (IFN-y) and interleukin-4 (IL-4) was detected from spleen lympholeukocyte of the immunized mice at 45 and 60 days post primary immunization to evaluate the cellular immune response. What is more, mice protection against JEV challenge was test. Results showed that the IgG1 isotype was induced by the rNS1 group alone. In contrast, mice immunized with the attenuated vaccine and pcDNA-NS1 alone elicited predominantly IgG2a.These results suggest that a mixed Th1/Th2 immune response was induced by DNA priming/protein boosting vaccine regimen. The pcDNA-NS1+rNS1 group is sufficient to protect mice against a lethal JEV challenge. Therefore, it can be an attractive candidate vaccine for preventing JEV infection.In summary, the results herein clearly illustrated that DNA/protein prime-boost vaccination strategy can produce high level antibody and trigger significant T cell and B cell responses, highlighting the potential value of such an approach in the prevention of JEV infection.

Related Dissertations

  1. Development of Subunit Vaccine of Streptococcus Suis Type 2 and Actinobacillus Pleuropneumoniae,S858.28
  2. Expression of IBDV Structural Protein VP2 Gene in Bombyx Mori and Its Immune Effect As Subunit Vaccine,S855.3
  3. Study on Pharmacokinetics and Spatial and Temporal Expression in Mice of DNA Vaccine against Schistosoma Japonicum,S855.91
  4. Study the Preparation Technology and the Preliminary Immune Effect Evaluation of Bovine Tuberculosis Trivalent DNA Vaccine,S858.23
  5. Construction of Coexpression Vector Containing Capripoxvirus P32 Gene and Goat CD58 Gene and Immune Activity Analysis of the Expression Production,S858.26
  6. Immune Responses to HBV Surface Protein Using DNA Prime and Prome and Protein Boost Stuategy in Balb/c Mice,R392
  7. Screen of A Membrane Protein Molecule from Vero Cells Capable of Binding Japanese Encephalitis Virus(jev),R373
  8. Immunoprotective Effects of DNA Vaccine of p55 Gene Fragment Against Pneumocystis Carinii,R392.1
  9. The Immunity Response in Mice of the Nucleic Acid Vaccine GAPDH in Brugia Malayi and the Gene Cloning of Bm-CPI,R392
  10. Construction and Immunity of the Recombinant DNA Vaccine Containing GP5, N Protein and Hsp70 Genes for Porcine Reproductive and Respiratory Syndrome,S852.659.6
  11. The Research of Recombinant IFN-a with PPV VP2-JEV E DNA Vaccine’s Immunogenicity,S852.5
  12. The Preliminary Study of the pcDNA3.1(+)-SjP14 Nanometer Microballoon-DNA Vaccines,R392.1
  13. Enhancement of Sj14-3-3 Induced Protective Immunity Against Schistosoma Japonicum Through Co-delivery of SjGST and Mouse Interleukin-12 CpG in a DNA Vaccine Formulation,R392
  14. Essential Sequences of Influenza A and B Virus Hemagglutinin DNA to Provide Protection Against Lethal Viral Infection,R373
  15. Protective Effect of a Multiantigenic DNA Vaccine Against Toxoplasma Gondii with Co-delivery of Interleukin-12 in BALB/c Mice,R392
  16. The Study of the Influence to Different Intensity Exercise on Mice CD4~+CD25~+ Regulatory T Cell and the Immune Effects of HBV DNA Vaccine,R392
  17. Construction of Human Cytomegalovirus IE1 DNA Vaccine and Primary Study of Its Immunocompetence in Mice,R392
  18. Construction and Identification of the Eukaryotic Expression Vector of pcDNA3.1+-P14 and GST of Schistosoma Japonicum and Investigation on Their Protective Effects,R392
  19. Evaluation of Mycobacterial Virulence Using Rabbit Skin Liquefaction Model and Study on Mycobacterium Tuberculosis Fusion Protein Subunit Vaccine,R392
  20. Preparation of Chitosan Nanoparticle Loaded with Helicobacter Pylori Lpp20 and Primary Study of Its Mucosal Vaccination in Mice,R392

CLC: > Medicine, health > Basic Medical > Medical Immunology
© 2012 www.DissertationTopic.Net  Mobile